Profile
| Metric | Value |
|---|---|
| Full Name | Celldex Therapeutics, Inc. |
| Ticker | NASDAQ: CLDX |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | celldex.com |
| Employees | 186 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $27.01 | |
| Price, 1D Change | -0.55% | |
| Market Cap | $2B | |
| - | ||
| PE Ratio | - | |
| Beta | 1.07 | |
| Revenue | $7M | |
| Revenue, 1Y Change | +1.99% | |
| EPS | -$2.45 | |
| EPS, 1Y Change | +16.02% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 1:15 | |
| Next Split | N/A | N/A |
| Last Ticker Change | AVAN | |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$2.45 | |
| EPS Estimate | -$3.58 | |
| EPS Est. Change | -45.87% | |
| Revenue | $7.02M | |
| Revenue Estimate | $2.79M | |
| Revenue Est. Change | -60.23% | |
| Current Price | $27.01 | |
| Price Target | - | $53.00 |
| Price Tgt. Change | - | +96.22% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$2.81 | -$2.92 | -3.88% | |
| -$2.35 | -$2.45 | -4.20% | |
| -$3.58 | N/A | -45.87% | |
| -$4.41 | N/A | -79.81% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $3.52M | $6.88M | +95.54% | |
| $6.86M | $7.02M | +2.28% | |
| $2.79M | N/A | -60.23% | |
| $3.56M | N/A | -49.29% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +4.73% | |
| Price, 3Y | -39.40% | |
| Market Cap, 1Y | +4.85% | |
| Market Cap, 3Y | -14.69% | |
| Revenue, 1Y | +1.99% | |
| Revenue, 3Y | +50.94% | |
| EPS, 1Y | +16.02% | |
| EPS, 3Y | -49.05% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $27.01 | |
| SMA 200 | $22.90 | |
| SMA 200 vs Price | -15.21% | |
| SMA 50 | $26.22 | |
| SMA 50 vs Price | -2.92% | |
| Beta | 1.07 | |
| ATR | $1.20 | |
| 14-Day RSI | 52.21 | |
| 10-Day Volatility | 43.32% | |
| 1-Year Volatility | 58.57% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $7.02M | |
| EPS | -$2.45 | |
| Gross Profit | $3.84M | |
| Gross Margin | 54.74% | |
| Operating Profit | -$195.08M | |
| Operating Margin | -2,778.89% | |
| Net Income | -$157.86M | |
| Net Margin | -2,248.76% | |
| EBITDA | -$191.90M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.00 | |
| Current Ratio | 18.91 | |
| Quick Ratio | 18.91 | |
| - | ||
| F-Score | - | |
| Altman Z-Score | 21.27 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | 690.31 | |
| PB Ratio | 3.00 | |
| EV/EBITDA | -4.83 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $747.01M | |
| Cash & Equivalents | $28.36M | |
| Total Assets | $792.34M | |
| Current Assets | $747.16M | |
| Total Liabilities | $45.34M | |
| Current Liabilities | $39.50M | |
| Total Debt | $3.81M | |
| Short Term Debt | $1.45M | |
| Accounts Payable | $3.27M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $202.10M | |
| Operating Expenses | $202.10M | |
| Cost Of Goods Sold | $3.18M | |
| SG&A | $38.55M | |
| D&A | $3.18M | |
| Interest Expense | $0.00 | |
| Income Tax | $0.00 |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$157.78M | |
| CFI | -$290.13M | |
| CFF | $441.45M | |
| Capex | $1.92M | |
| Free Cash Flow | -$159.70M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Barclays | → | |
| Barclays | → | |
| Mizuho | ||
| Barclays | ||
| Canaccord Genuity | → | |
| Wells Fargo | → | |
| HC Wainwright & Co. | → | |
| Citigroup | → | |
| Canaccord Genuity | → | |
| HC Wainwright & Co. | → |
Analyst sentiment
Institutional ownership
Screeners with CLDX
Data Sources & References
- CLDX Official Website www.celldex.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/744218/000110465925109137/0001104659-25-109137-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/744218/000141057825000216/0001410578-25-000216-index.htm
- CLDX Profile on Yahoo Finance finance.yahoo.com/quote/CLDX
- CLDX Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/cldx
FAQ
What is the ticker symbol for Celldex Therapeutics, Inc.?
The ticker symbol for Celldex Therapeutics, Inc. is NASDAQ:CLDX
Does Celldex Therapeutics, Inc. pay dividends?
No, Celldex Therapeutics, Inc. does not pay dividends
What sector is Celldex Therapeutics, Inc. in?
Celldex Therapeutics, Inc. is in the Healthcare sector
What industry is Celldex Therapeutics, Inc. in?
Celldex Therapeutics, Inc. is in the Biotechnology industry
What country is Celldex Therapeutics, Inc. based in?
Celldex Therapeutics, Inc. is headquartered in United States
When did Celldex Therapeutics, Inc. go public?
Celldex Therapeutics, Inc. initial public offering (IPO) was on May 15, 1986
Is Celldex Therapeutics, Inc. in the S&P 500?
No, Celldex Therapeutics, Inc. is not included in the S&P 500 index
Is Celldex Therapeutics, Inc. in the NASDAQ 100?
No, Celldex Therapeutics, Inc. is not included in the NASDAQ 100 index
Is Celldex Therapeutics, Inc. in the Dow Jones?
No, Celldex Therapeutics, Inc. is not included in the Dow Jones index
When was Celldex Therapeutics, Inc. last earnings report?
Celldex Therapeutics, Inc.'s most recent earnings report was on November 10, 2025
When does Celldex Therapeutics, Inc. report earnings?
The next expected earnings date for Celldex Therapeutics, Inc. is February 26, 2026